The antidepressant-like effect of a supercritical CO 2 (SCCO 2 ) Valeriana glechomifolia extract enriched in valepotriates was investigated in a mice tail suspension test (TST) and forced swimming test (FST). The SCCO 2 extract decreased mice immobility in the FST (0.5-20 mg/kg p.o.) and elicited a biphasic dose-response relationship in the TST (1-20 mg/kg p.o.) with no alterations in locomotor activity and motor coordination (assessed in the open-field and rota-rod tests, respectively). The anti-immobility effect of the SCCO 2 extract (5 mg/kg, p.o.) was prevented by mice pre-treatment with yohimbine (1 mg/kg, i.p., an α2 adrenoceptor antagonist), SCH 23390 (15 μg/kg, s.c., D 1 dopamine receptor antagonist) and sulpiride (50 mg/kg, i.p., D 2 dopamine receptor antagonist). However, mice pre-treatments with prazosin (1 mg/kg, i.p., α1 adrenoceptor antagonist) and p-chlorophenilalanine methyl ester (4 × 100 mg/kg/day, i.p., a serotonin synthesis inhibitor) were not able to block the anti-immobility effect of the SCCO 2 extract. Administration (p.o.) of the SCCO 2 extract (0.25 mg/kg) and imipramine (10 mg/kg), desipramine (5 mg/kg) and bupropion (3 mg/kg) at subeffective doses significantly reduced mice immobility time in the FST. These data provide the first evidence of the antidepressant-like activity of V. glechomifolia valepotriates, which is due to an interaction with dopaminergic and noradrenergic neurotransmission.
Introduction
Depression is a high prevalence mood disorder (Berton and Nestler, 2006) associated with a heavy social burden (Greenberg et al., 2003) . The neurobiology of this disease is still uncompletely understood but the role of monoaminergic system is accepted (Nutt, 2008) . In line with this, the antidepressants currently available boost the synaptic action of one or more of the three monoamines (serotonin, noradrenalin and dopamine) by blocking the neuronal reuptake of these neurotransmitters (Lambert et al., 2000; Stahl, 2008) . Nevertheless, the pharmacotherapy employed in the treatment of depression produces several adverse side effects (Brunello et al., 2002 ) and a significant number of individuals do not respond to any antidepressant (Berton and Nestler, 2006; Nestler et al., 2002) . Thus, there is a need to search for new compounds and strategies of treatment that could improve conventional therapies. In this context, natural products research has been considered as an option for the development of drugs with innovative mechanisms of action and/or conceivably minimized adverse side effects (Wang et al., 2008) .
Among alleged neuroactive natural products, Valeriana genus is widely studied, with special focus on anxiolytic properties (Hattesohl et al., 2008; Murphy et al., 2010) . Besides being the most popular herbal supplement for the treatment of anxiety and mild sleep disorders, preclinical studies reported the antidepressant-like activity of V. officinalis (Hattesohl et al., 2008) , V. wallichii (Sah et al., 2011; Subhan et al., 2010) and V. prionophylla (Holzmann et al., in press ). Moreover, the clinical efficacy of these species in improving depression symptoms was also demonstrated (Bhattacharyya et al., 2007) .
The molecular mechanisms responsible for these effects have not been completely elucidated, although some studies point to a stimulation of GABA neurotransmission underlying anxiolytic properties (Cavadas et al., 1995; Mennini et al., 1993; Ortiz et al., 2004) .
Valeriana contains over 135 chemical constituents (Wang et al., 2010) , comprising the volatile oil, flavonoids (Marder et al., 2003) and valepotriates (epoxy iridoid esters) (Backlund and Moritz, 1998) . The identity of bioactive substances is somewhat controversial but there is evidence that valepotriates substantially contribute to the pharmacological properties of plants belonging to this genus. Mennini et al. (1993) demonstrated that diidrovaltrate binds to a barbiturate site of a GABA A receptor and, therefore, contributes to the pharmacological activity of the Valeriana genus. On the other hand, Lacher et al. (2007) showed that isovaltrate is a potent inverse agonist of adenosine A1 receptors, which may counteract the desired sedative effect of the genus. Estrada-Soto et al. (2010) demonstrated that a hydroalcoholic extract from V. edulis ssp. procera enriched in valepotriates relaxes isolated rat aorta by blocking calcium channels and previous reports have shown that isovaltrate and valtrate cause a suppression of rhythmic contractions in guinea-pig ileum in vivo and in vitro (Hazelholff et al., 1982) . The citotoxic effects of valepotriates in vitro were already demonstrated (Bounthanh et al., 1983; Lin et al., 2009 ). However, in vivo experiments have not demonstrated toxicity in rats orally administered with valepotriates (Tufik et al., 1994) . In summary, literature data regarding the pharmacological activity of valepotriates are not very extensive and present some dissonant results. Thus, further studies on the central effects of these compounds are needed.
Among the species native to southern Brazil, V. glechomifolia is the most studied, and is the only one that accumulates valepotriates in both aerial and subterranean parts (Silva et al., 2002) . Although this species is not used in traditional medicine, Maurmann et al. (2009) demonstrated that a valepotriate fraction of V. glechomifolia has sedative and anxiolytic effects and induces alterations in mice recognition memory. Recently, Bettero et al. (2011) demonstrated that valtrate, acevaltrate and 1-β-acevaltrate from V. glechomifolia show inhibitory activity toward Na + K + ATPase from rat brain in vitro.
This could be particularly relevant since this enzyme activity is changed in mood disorders (El-Mallakh and Wyatt, 1995) and the antidepressant imipramine also inhibits its activity in rat cortex in vitro (Zanatta et al., 2001) . Considering that the antidepressant-like effect of V. glechomifolia has not been explored yet and central effects of valepotriates are not completely ascertained, the aim of this study was to investigate the potential antidepressant effect of a SCCO 2 V. glechomifolia extract enriched in valepotriates by using tail suspension and forced swimming tests in mice, which are animal models used to screen new antidepressant drugs. The contribution of monoaminergic neurotransmission (serotonergic, noradrenergic and dopaminergic) to the antidepressant-like effect was also investigated.
Materials and methods

Animals
Male CF1 mice (25-30 g) were purchased from Fundação Estadual de Produção e Pesquisa em Saúde, RS (Brazil). The animals were housed in plastic cages (17 × 28 × 13 cm), five mice per cage, and kept under a 12 h light/dark cycle (lights on between 7:00 h and 19:00 h) at constant temperature of 23°± 1°C with free access to standard certified rodent diet and tap water. All behavioral experiments were approved by The Animal Care Local Ethical Committee (CEUA-UFRGS; projects approval number 19022) and performed according to the European Communities Council Directive of 24 November 1986 (86/609/EEC) . In this study, 570 animals were used. Except for rota-rod experiments, all animals were used only once. 
Plant material
Chemicals and drugs
For the extract characterization, grade HPLC acetonitrile and methanol were purchased from Merck® (Germany). For the behavioral experiments, the following drugs were used: fluoxetine, sulpiride and imipramine hydrochloride from Galena® (Porto Alegre, Brazil), bupropion from Eurofarma® (Brasil) and pCPA, SCH23390, prazosin, yohimbine and desipramine which were purchase from Sigma Chemical Co. (St. Louis, MO, USA). All drugs were dissolved in normal saline and the extract was suspended in saline with 1% of polysorbate 80 (vehicle) prior to use. Drug concentrations in saline solution were: imipramine-2 mg/ml and 1 mg/ml; fluoxetine-3 mg/ml and 1.5 mg/ml; desipramine-0.5 mg/ml; bupropion-0.3 mg/ml; SCH23390-0.5 mg/ml; sulpiride-5 mg/ml; prazosin and yohimbine-0.1 mg/ml and pCPA-10 mg/ml. The SCCO 2 extract was suspended in vehicle at different concentrations depending on the dose required: 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.1 mg/ml, 0.05 mg/ml and 0.025 mg/ml.
Supercritical extraction
Apparatus
The supercritical extraction was performed in a Pilot Equipment (Cassel et al., 2010) . The SCCO 2 flowed at rate of 6.67 × 10 −4 kg s
through the extraction vessel. The extraction vessel was supplied with a heating jacket and an automated temperature controller, and heating tapes were used throughout the apparatus to maintain constant temperature in the extraction section. To ensure constant and steady solvent delivery the pump head was cooled by a circulating fluid, which passed through a chiller. Flow rates and accumulated gas volumes passing through the apparatus were measured using a flowmeter assay, 1-300 g/min (Thar 06618-2, USA). Ke (USA) micrometering valves (VC1) were used for flow control throughout the apparatus. Heating tapes with automated temperature control were also used around this valve to prevent both freezing of the solvents and solid solute precipitation following depressurization. Pressure in the extractor was monitored with a digital transducer system, Novus 8800021600, acquired from Novus Produtos Eletrônicos (Brazil) with a precision of ± 1.0 bar. The temperature controller (TC) was connected to thermocouples (PT-100), with an accuracy of 0.5 K.
Extract preparation
Powdered aerial and underground plant material (120 g dry weight) was used and the extraction was conducted at constant temperature (40°C) and pressure (90 bar). The extract was collected every 30 min and taken to a circulating air oven (40°C), until the complete evaporation of the water condensed in the extract due to Joule-Thompson cooling. The SCCO 2 extraction yield recovery was 2.72 g%.
Determination of diene valepotriates content
Diene valepotriate characterization and quantification of the extract were performed by HPLC analysis, using the method previously validated by Silva et al. (2002) using a Shimadzu HPLC system (LC-6AD pump, SPD-20AV UV detector and automatic injector SIL-20 AC). A Waters Nova-Pack C18 column (4 μm, 3.9× 150 mm i.d. with Waters NovaPack C18 guard column, 60 Å, 3.9 ×20 mm) was the stationary phase; the mobile phase consisted of acetonitrile and water as isocratic solvent (50:50 v/v); with a flow rate of 1 mL min − 1 and detection at 254 nm.
Valtrate, the valepotriate found in larger quantities in V. glechomifolia, was used as external standard. For the calibration curve achievement, valtrate was isolated from the extract through column chromatography, with silica gel stationary phase and mobile phase gradient with n-hexane: dichloromethane. The fractions obtained were monitored by thin layer chromatography, with standard valtrate, gathered and taken to dryness in a rotary evaporator. Linearity analysis of the calibration curve revealed R 2 =0.9983. All diene valepotriates were quantified in mg of valtrate equivalent (VE)/g extract.
Tail suspension test
The TST was conducted according to Steru et al. (1985) with minor modifications (Duarte et al., 2008) . Mice were adapted to the laboratory conditions 1 h before the exposition to TST. The animals, under acoustic and visual isolation, were suspended by the tail 60 cm above the floor using adhesive tape (1 cm from the tip of the end) in a dim light room. Immobility time was recorded (in seconds) during the last 4 min of a total 6 min session (Kwon et al., 2010) . Mice were considered immobile when they hung passively and completely motionless. The animals (n = 10 per group) were treated orally 1 h before being submitted to the TST; different groups received vehicle (10 ml/kg), fluoxetine (30 mg/kg, positive control), SCCO 2 extract from V. glechomifolia (1, 5, 10 and 20 mg/kg). The immobility behavior was recorded by human observers blind to the treatment.
Forced swimming test
The FST was carried out according to Porsolt et al. (1977) with minor modifications standardized and validated in our laboratory (Viana et al., 2005) . Mice were adapted to the laboratory conditions 1 h before being exposed to FST. The animals were individually forced to swim in a cylinder pool (10 cm diameter, 13 cm height, water at 22°± 1°C) and the total duration of immobility during a 6 min test was scored (in seconds). Each mouse was recorded as immobile when it remained floating motionless or making only the movements necessary to keep its head above water. The immobility behavior was recorded by human observers blind to the treatment.
Treatments
Animals (n = 8 per group) were orally treated (10 ml/kg) with imipramine (20 mg/kg, positive control), SCCO 2 extract from V. glechomifolia (0.25; 0.5; 1; 5; 10; 20 mg/kg) or vehicle, 1 h before being submitted to the FST.
To access the time-course of the antidepressant-like effect of the SCCO 2 extract from V. glechomifolia (5 mg/kg), the immobility time in the FST was recorded in independent groups of mice (n = 9 per group), 1, 2 and 3 h after the oral administration of the SCCO 2 extract or vehicle.
The antidepressant-like effect of sub-effective doses of conventional antidepressants combined with a sub-effective dose of the SCCO 2 extract was also investigated. For this purpose, mice (n = 8-10 per group) were orally treated with imipramine (10 mg/kg, a noradrenaline and serotonin reuptake inhibitor), desipramine (5 mg/kg, a noradrenaline reuptake inhibitor), bupropion (3 mg/kg, a dopamine reuptake inhibitor) or fluoxetine (15 mg/kg, a serotonin reuptake inhibitor) and immediately after, a sub-effective dose of the SCCO 2 extract (0.25 mg/kg p.o.) or vehicle was administered. After 1 h, the FST was carried out.
In order to assess the possible involvement of the noradrenergic neurotransmission on the antidepressant-like effect of the SCCO 2 extract in the FST, mice (n= 8-10 per group) were pretreated with prazosin (1 mg/kg, i.p., an α1 adrenoceptor antagonist); yohimbine (1 mg/kg, i.p., an α2 adrenoceptor antagonist) or vehicle. After 30 min they received the SCCO 2 extract (5 mg/kg, p.o.) or vehicle, and were submitted to the FST 1 h later.
The contribution of the dopaminergic neurotransmission to the antidepressant-like effect of the SCCO 2 extract was evaluated by using dopamine receptor antagonists. Animals (n = 8-10 per group) were pretreated with sulpiride (50 mg/kg, i.p., a D 2 antagonist) or SCH 23390 (15 μg/kg, s.c., a D 1 antagonist) 30 min before the administration of the SCCO 2 extract (5 mg/kg p.o.). One hour later, the animals were submitted to the FST.
For evaluating the serotonergic neurotransmission, mice (n = 8-12 per group) were pretreated with pCPA (100 mg/kg, i.p., an inhibitor of serotonin synthesis) or saline, once a day, for 4 consecutive days. Twenty-four hours after the last pCPA or saline injection, animals were treated with the SCCO 2 extract (5 mg/kg, p.o.), or vehicle and were tested in the FST 1 h later.
The drug doses were chosen on the basis of previous results obtained by our research group (Viana et al., 2005) and on literature data (Jesse et al., 2010; Wang et al., 2008) .
Open-field test
The OFT was performed in order to evaluate the possible effects of the SCCO 2 extract as well as its association with antidepressant subeffective doses on the locomotor and exploratory activities. For this purpose, mice (n = 10-12) received those treatments that significantly reduced the immobility time in FST 1 h before being observed in the open-field. Animals were individually placed in an acrylic box (40 × 30 × 30 cm), with the floor divided into 24 equal squares. After the habituation to the arena for 5 min, the number of squares crossed with the four paws (crossing) and rearing was recorded in a 15 min session, by human observers blind to the treatment. The apparatus was cleaned with 10% ethanol after each mouse exposition.
Rota-rod test
The rota-rod test was carried out to assess the possible effects of the SCCO 2 extract on the integrity of mice motor coordination as described by Neves et al. (2010) . The apparatus consisted of a cylinder of 3 cm of diameter rotating at 5 rpm. Initially, the animals were individually habituated to the apparatus for 5 min. Twenty four hours later, the animals were trained for 5 min and only the ones that were able to stay balanced on the rotating rod for 90 s were selected for testing. Immediately after, mice were orally treated with the SCCO 2 extract (0.5; 5 and 20 mg/kg) or vehicle. One hour later, mice performance in the rota-rod was evaluated by human observers blind to the treatment, considering the longest time of permanence on the apparatus and the number of falls, in a 5 min period.
Statistical analysis
Results obtained in the FST, TST and OFT were analyzed by one or two-way ANOVA followed by Student-Newman-Keuls test when appropriate. Rota-rod test results were analyzed by two-way ANOVA with repeated measures (being the treatment the first factor and the session, second factor, the repeated-measure). The level for statistical significance was set as p b 0.05. The statistical procedures were performed using the Sigma Stat software 2.03 (Jandel Scientific Corporation).
Results
Diene valepotriates from SCCO 2 V. glechomifolia extract
Diene valepotriates content from the SCCO 2 extract determined by HPLC analysis is shown in Table 1 and each valepotriate chemical structure is presented in Fig. 1 . The valepotriate found in larger quantity was valtrate (474.23 mg/g), followed by acevaltrate (173.09 mg/g), 1-β-acevaltrate (55.3 mg/g), 1-β-aceacevaltrate (37.57 mg/g) and isovaltrate (32.68 mg/g).
Antidepressant-like effect in the TST and FST
The effects of the SCCO 2 extract acute administration in the FST and TST are shown in Fig. 2A and B, respectively. One-way ANOVA revealed a significant main effect of the SCCO 2 extract in the FST [F(7,55) =12.98; p b 0.001] (Fig. 2A) . Post hoc analysis indicated a significant decrease in mice immobility time caused by the positive control imipramine (p b 0.001) and SCCO 2 extract administration at 0.5 (p b 0.05), 1, 5, 10 and 20 mg/kg (p b 0.001) when compared to vehicle-treated group. In addition, the immobility time of mice that were administered with SCCO 2 extract 0.5 mg/kg was significantly higher (p b 0.05) than the immobility time of the groups that received the SCCO 2 extract at 1-20 mg/kg, characterizing a dose-response relationship.
One-way ANOVA revealed a significant main effect of the SCCO 2 extract [F(5,59) = 5.71; p b 0.001] in the TST (Fig. 2B) . Post hoc analysis indicated a significant decrease in the immobility time elicited by the administration of the SCCO 2 extract at doses of 5 (p b 0.05) and 10 mg/kg (p b 0.01) and the positive control fluoxetine at 30 mg/kg (p b 0.001), when compared with vehicle-treated group. SCCO 2 extract did not show any anti-immobility effect in the TST at the lowest (1 mg/kg) and highest (20 mg/kg) tested doses, indicating a bellshaped dose-response relationship.
A time-course analysis of the antidepressant-like effect of the SCCO 2 extract was accomplished in the FST (Fig. 3) . The antidepressant-like activity of the SCCO 2 extract reached its peak in 1 h, remained significant up to 2 h [one-way ANOVA: F(3,35) = 24.12; p b 0.001] and this effect was abolished 3 h after treating. The administration of the SCCO 2 extract (0.5; 5 and 20 mg/kg) did not alter the locomotor activity in OFT neither the motor coordination integrity assessed by the rota-rod test (Table 2) . Considering these results, the time point of 1 h and the dose of 5 mg/kg were chosen for all further experiments. Also, the SCCO 2 extract sub-effective dose of 0.25 mg/kg was selected to be employed in combination with antidepressant sub-effective doses in the FST. (Fig. 4A) .
Interaction of the SCCO 2 extract with antidepressants in the FST
Likewise, the co-administration of sub-effective doses of desipramine (5 mg/kg, p.o.) and SCCO 2 extract (0.25 mg/kg p.o.) elicited an (Fig. 4B ). Fig. 4C shows that the effect of bupropion at a sub-effective dose (3 mg/kg, p.o.) was amplified when it was associated with a subeffective dose of the SCCO 2 extract (0.25 mg/kg, p.o.) in the FST (38.8% of reduction in the immobility time) [one-way ANOVA: F(3,35) = 11.11; p b 0.001].
The combination of a sub-effective dose of fluoxetine (15 mg/kg, p.o) with the SCCO 2 extract sub-effective dose did not elicit any antidepressant-like effect in the FST (one way ANOVA: F(3,35) = 0.85; p =0.475] (Fig. 4D) .
The association of all antidepressant drugs tested with SCCO 2 extract did not affect locomotor and exploratory activities assessed in the OFT (Table 2) . 
Involvement of serotonergic neurotransmission in the antidepressant-like effect of the SCCO 2 extract in the FST
The pretreatment of mice with pCPA (100 mg/kg, i.p., once a day for 4 consecutive days) was not able to prevent the effect of the SCCO 2 extract on the FST (Fig. 5E ). Two-way ANOVA did not reveal a main effect of pCPA pretreatment [F(1,34) = 2.50; p = 0.123] nor a pCPA × SCCO 2 extract interaction [F(1,34) = 0.14; P = 0.71], but a significant main effect of the SCCO 2 extract [F(1,34) = 18.83; p b 0.001].
Discussion
In the present study we have shown for the first time, to our knowledge, the antidepressant-like effect of a SCCO 2 V. glechomifolia extract enriched in valepotriates in both TST and FST, which are predictive of antidepressant activity (Bourin et al., 2005) . This effect was not related to a non-specific behavioral alteration, given that the SCCO 2 extract did not alter locomotor activity or motor coordination. Furthermore, it was demonstrated that SCCO 2 extract antidepressantlike effect seems to be mediated by an interaction with the dopaminergic and noradrenergic neurotransmission, but not with the serotonergic neurotransmission. These findings are in accordance to Sah et al. (2011) that reported the antidepressant-like effect of a V. wallichii dichloromethane extract (containing mainly valepotriates) in mice FST, which is mediated by noradrenergic and dopaminergic neurotransmission, with no significant dependence on the serotonergic neurotransmission.
The antidepressant-like effect of the SCCO 2 extract was more pronounced in the FST in comparison to the TST, since the SCCO 2 extract at 0.5 mg/kg significantly reduced the immobility time of the animals in the FST, whereas this effect was observed only at 5 mg/kg in the TST, where a bell-shaped dose-response relationship was found. Although both TST and FST are alike in some aspects, they have differences involving the substrates and neurochemical pathways that are related to the performance on these tests (Bai et al., 2001) . The TST is widely employed to detect potential antidepressants that act mainly on the serotonergic neurotransmission, since this test is more sensitive than the FST to these drugs (Cryan et al., 2005; Porsolt et al., 1991) . Hence, the less pronounced action of the SCCO 2 extract on the TST suggests that serotonergic neurotransmission is not important for its effect. This hypothesis was supported by our subsequent experiments.
Our results demonstrated that the anti-immobility effect of the SCCO 2 extract on the FST was completely prevented by pretreatment with yohimbine, SCH 23390 and sulpiride whereas pretreatment with pCPA was not able to prevent it, indicating that the effect of the SCCO 2 extract depends mainly on noradrenergic (via α2 receptor) and dopaminergic (via D 1 and D 2 receptors) neurotransmission.
Literature data show the involvement of α2 adrenoceptor and dopaminergic receptors in the action of some antidepressants (Gherson et al., 2007; Paparrigopoulos et al., 2001; Porcelli et al., 2011) : D1 and D2 receptor agonists, as well as drugs that increase dopamine function, have an antidepressant-like profile in patients and animal models of depression (D'Aquila et al., 2000; Picillo et al., 2010; Sato et al., 2010) ; O'Neill and Conway (2001) demonstrated that the antidepressant-like effect of clonidine (α2 adrenoceptor agonist) in the FST was prevented by the pretreatment with yohimbine.
The SCCO 2 extract was able to potentiate the effect of the conventional antidepressants imipramine, desipramine and bupropion in FST, with no behavioral stimulation, whereas the combined administration of the SCCO 2 extract and fluoxetine did not produce any antiimmobility effect corroborating with the hypothesis that the serotonergic neurotransmission is not directly involved in the mode of action of the SCCO 2 extract and pointing to the activation of noradrenergic and dopaminergic neurotransmitter systems. Considering that postsynaptic α2 adrenoceptors play an important role in desipramine antidepressant effects (Zhang et al., 2009 ) and mice pre-treatment with yohimbine completely prevented the effects of the SCCO 2 extract in the FST, we may infer that these postsynaptic receptors are involved in the antidepressant-like effect of the SCCO 2 extract.
Altogether the results from our study suggest that the SCCO 2 extract presents a dual-action distinct from most of the conventional antidepressants. Novel agents with multiple and distinct therapeutic mechanisms are needed since they may show a good response in selective serotonin reuptake inhibitor (SSRI)-resistant patients (Fava, 2000; Ruhé et al., 2006) . Currently, the most frequently prescribed class of dual-action antidepressants is serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine, duloxetine and milnacipram, which increase the levels of both neurotransmitters within the central nervous system by selectively inhibiting their reuptake in the synaptic clefts (Stahl, 2008) . Nevertheless, there are depressed patients (especially those not responding to standard SSRIs and SNRIs) that require treatment with more powerful dopaminergic effects, since these drugs may improve residual symptoms related to a deficiency in the mesolimbic dopamine system, including impaired motivation, concentration, and pleasure (Dunlop and Nemeroff, 2007) . Moreover, there are converging evidence demonstrating that compounds acting on the noradrenergic neurotransmission are more effective in the treatment of severe depression than those with an exclusive serotonergic mechanism (Brunello et al., 2002; Dell'Osso et al., 2010) . Currently, the prototypical agent of dual-action noradrenergic and dopaminergic antidepressants is bupropion, which has proven to be a useful antidepressant for the treatment of SSRI or SNRI-resistant depression (Baumann, 2007) . Considering these literature data, the dual-action of the SCCO 2 extract observed here point to valepotriates as promising agents for developing new antidepressants to treat those patients for whom the serotonergic action is not enough.
Furthermore we can suggest that the combination of SCCO 2 V. glechomifolia extract as well as other Valeriana species with conventional antidepressants may be a promising approach for further studies on the treatment of depression. Some authors have been considering the adjuvant use of herbal medicines valuable to enhance the response and improve efficacy of synthetic antidepressants and decrease their side-effects by allowing lower doses to be prescribed (Sarris et al., 2010) . In fact, in several cases the antidepressant pharmacotherapy is poorly tolerated due to the adverse side effects of conventional drugs, which include sexual dysfunction, insomnia, gastrointestinal disorders, hypotension and dizziness (Berton and Nestler, 2006) . Combining antidepressants from different classes represents an alternative strategy to exploit potential synergies among two or more independent therapeutic mechanisms for treating refractory patients. The main advantage of this approach is decreased doses of antidepressants prescribed and consequently the adverse side effects (Lam et al., 2002) . and pCPA (100 mg/kg/day, i.p., panel E) on the anti-immobility effect of the SCCO 2 extract (5 mg/kg, p.o.) in the FST. Each column represents the mean ± S.E.M (n = 8-12 mice/group). Two-way ANOVA followed by Student-Newman-Keuls: **p b 0.01 ***p b 0.001 when compared to the vehicle-treated group.
Conclusion
In conclusion, the results obtained in this study provided the first evidence of the antidepressant-like effect of V. glechomifolia and indicate the valepotriates as new promising chemical entities for developing new antidepressant drugs. It was shown that this effect is mediated by dopaminergic (D 1 and D 2 receptors) and noradrenergic (α2 receptor) neurotransmission, which represents a dual-action different from most of the available antidepressants. Further studies are in progress to determine which valepotriates are responsible for the antidepressant-like activity of SCCO 2 V. glechomifolia extract as well as to elucidate their molecular target.
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